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ABSTRACT Extracorporeal membrane oxygen (ECMO) has been used for many years in patients with
life-threatening hypoxaemia and/or hypercarbia. While early trials demonstrated that it was associated
with poor outcomes and extensive haemorrhage, the technique has evolved. It now encompasses new
technologies and understanding that the lung protective mechanical ventilation it can facilitate is
inextricably linked to improving outcomes for patients.
The positive results from the CESAR (Conventional ventilation or ECMO for Severe Adult Respiratory
failure) study and excellent outcomes in patients who suffered severe influenza A (H1N1/09) infection have
established ECMO in the care of patients with severe acute respiratory distress syndrome. Controversy
remains as to at what point in the clinical pathway ECMO should be employed; as a rescue therapy or more
pro-actively to enable and ensure high-quality lung protective mechanical ventilation.
The primary aims of this article are to discuss: 1) the types of extracorporeal support available; 2) the
rationale for its use; 3) the relationship with lung protective ventilation; and 4) the current evidence for its use.
@ERSpublications
ECMO and ARDS are inextricably linked to lung protection but when is tidal ventilation too
injurious? http://ow.ly/yUJl7
Introduction
Variations of cardiopulmonary bypass have been used successfully in patients with severe acute respiratory
distress syndrome (ARDS) since 1972 [1]. In a condition defined, in part, by refractory hypoxaemia its use is
appealing. However, outcomes in early clinical trials were very poor [2, 3], and it was associated with severe
haemorrhagic complications. Over the past 5 years, there has been an explosion in the number of patients
receiving extracorporeal support for respiratory failure according to data from the international registry
hosted by the Extracorporeal Life Support Organisation (ELSO). The associated increase in publications,
including this one, and the flurry of hospitals opening ‘‘extracorporeal membrane oxygen (ECMO) centres’’
mirrors the enthusiasm for extracorporeal support and is a far cry from the time when many considered the
practice as futile. What underpins the change in practice? Does ECMO support have a role in the care of
patients with severe ARDS? When should it be employed in the complex patient pathway [4], which includes
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diagnosis, fluid management, careful mechanical ventilation, prone ventilation [5] and the avoidance of
complications such as ventilator associated pneumonia?
Terminology
Extracorporeal life support (ECLS) is an umbrella term for all extracorporeal systems that provide support
for the failing lung, heart or both. ECLS includes ECMO. During ECMO, a patient’s blood is pumped
through a membrane lung or oxygenator containing hollow polymethylpentene microfibres. Oxygen-
containing gas passes through these microfibers, across the microfiber walls of which gas exchange occurs.
If blood is taken from the venous circulation and returned to the venous circulation (venovenous ECMO)
then gas exchange occurs in a pre-pulmonary position and the effects of poor native lung function are
obviated (fig. 1). Indeed, pre-pulmonary oxygenation can disrupt hypoxic pulmonary vasoconstriction
further reducing the contribution of the native lung to gas exchange [6]. Venovenous ECMO has few
circulatory effects aside from those resulting in a reduction in the pulmonary vascular resistance and
modified cardiac preload, which occur due to oxygenation of pulmonary arterial blood, reduced
hypercapnia, and the ability to reduce driving pressures on the mechanical ventilator.
In contrast, during venoarterial ECMO blood is passed from the venous to the arterial system and the flow of
oxygenated blood into the arterial tree contributes to the global ‘‘cardiac’’ output of the body, thereby
providing cardiac and respiratory support. Venoarterial ECMO may be peripheral, central or a hybrid of both,
depending on the location of the cannulae that provide access to the circulation (fig. 2). Centrally positioned
venous and arterial cannulae are usually in the right atrium and aortic root, respectively. Peripherally
positioned venous and arterial cannulae are usually in the femoral/jugular veins and femoral/subclavian/
carotid arteries, respectively. Peripheral femoral arterial access results in retrograde flow in the aorta.
Technology
Modern ECMO circuits are relatively simple loops of tubing containing a pump and membrane (fig. 3). The
technology has improved markedly with centrifugal pumps being employed in preference to roller pumps,
polymethylpentene microfibre oxygenators used rather than silicone oxygenators, and bonding of anti-
thrombotic agents to the inner lumen of the circuit. These anti-thrombotic agents are proprietary to
different manufacturers, but include covalent bound heparins (e.g. Bioline (Maquet, Rastatt, Germany),
Carmeda (Carmeda AB, Upplands Vasby, Sweden) and Rheoparin (Medos AG, Stolberg, Germany)) or
hydrophobic/hydrophilic polymers (e.g. Softline (Maquet)). Cannulae have also improved, offering less
resistance to flow, anti-thrombotic coatings and designs that minimise recirculation when in a dual lumen
configuration. Together, these technological advances have simplified the circuit, made it less traumatic to
blood and its components, reduced the need for anticoagulation, reduced the degree of systemic
inflammation triggered by the circuit, and reduced the complications from a patient’s perspective.
Undoubtedly, the newer technology has eased the wider adoption of ECMO, but probably also shifted the
risk–benefit balance in favour of ECMO support.
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FIGURE 1 Common venovenous extracorporeal membrane oxygen configurations. a) Femoral–jugular cannulation,
b) bicaval dual lumen cannulation of the right internal jugular, and c) femoral–femoral cannulation.
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Gas exchange in the membrane lung
Gas exchange occurs across the walls of the microfibres in the membrane lung, which is governed by the
principles of Fick’s law of diffusion. The concentration gradient driving the flow of gas is the difference
between the partial pressure of oxygen or carbon dioxide in blood and the sweep gas passing through the
hollow fibres. During venovenous ECMO, blood entering the membrane lung has its oxygen saturation
increased to 100% (fig. 4a). This equates to an increase of ,35% and an increase in oxygen content of
,50 mL?L-1. Oxygen uptake is enhanced by the simultaneous removal of carbon dioxide and alkalinisation
of blood as it passes through the membrane lung (Bohr effect). To fulfil the resting oxygen requirements of
an adult (,250 mL?min-1), an ECMO blood flow of ,5 L?min-1 would be needed. Systemic arterial
saturations do not increase to 100% due to recirculation and the fact that the newly oxygenated blood is
mixed with venous blood that has bypassed the cannula, which is effectively a physiological shunt. The
oxygen content of blood in the circuit cannot be increased further within the circuit due to the 100% upper
limit on saturations and the relative poor solubility of oxygen in plasma. Patient oxygenation can only be
improved by increasing blood flow through the circuit and oxygenating proportionally more of the cardiac
output. In practice, ECMO blood flow should be around two-thirds of the patient’s cardiac output to
provide acceptable arterial saturations. This can be difficult to achieve in patients who have sepsis and high
cardiac outputs.
During venovenous ECMO, the greater solubility of blood for carbon dioxide and the flatter relationship
between carbon dioxide tension and content means that the membrane lung removes ,150 mL?L-1 of
carbon dioxide from the blood (fig. 4b). Thus, the carbon dioxide production of a resting adult can be
effectively removed at a blood flow of only 1.3 L?min-1. The Haldane effect enhances carbon dioxide
removal as the blood is simultaneously oxygenated. The required blood flow is considerably less than that
needed to support oxygenation, which has led to the development of several lower flow devices that aim to
provide primarily extracorporeal carbon dioxide removal (ECCO2R) rather than oxygenation. Examples
include the interventional Lung Assist (iLA; Novalung GmbH, Heilbronn, Germany), iLA Activve
(Novalung GmbH), Hemolung (ALung Technologies Inc., Pittsburgh, PA, USA) and Pump-Assisted Lung
Protection on the CardioHelp platform (Maquet, Rastatt, Germany). The advantages of lower flow devices
have yet to be confirmed but may include the ability to use smaller, easier to place cannulae and less blood
trauma due to the reduced shear stresses and reduced circuit pressures. The devices may be useful when
hypercapnia but not hypoxaemia dominates the clinical scenario.
Rationale
Venovenous ECMO
Venovenous ECMO can restore the arterial blood gases of patients with refractory hypoxaemia and
impaired tissue oxygen delivery or life threatening hypercarbia. Venovenous ECMO has often been
deployed in these crises. It can also be used to facilitate lung protective ventilation, a central tenet in the care
of patients with severe ARDS [7]. Indeed, ECMO and lung protective ventilation are inextricably linked.
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FIGURE 2 a) Venoarterial and b) venovenous arterial extracorporeal membrane oxygen configurations.
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The landmark ARMA study published in 2000 demonstrated that patients with ARDS who received lower
tidal volumes had reduced mortality, probably due to the associated reduction in multi-organ failure and
systemic inflammation [8]. Tidal volume reduction is associated with arterial hypercapnia. Whilst this can
be mitigated by increasing the respiratory frequency, lower respiratory rates may be protective in animal
models of ventilator-induced lung injury [9, 10] and facilitate the prolongation of the inspiratory time,
which in turn may enhance oxygenation through recruitment of long time-constant lung units.
Oxygenation can be improved by high inspired oxygen concentrations or high airway pressures that may
open up lung units. However, high airway pressures can cause cardiovascular compromise or injurious over
distension of other areas of the lung. Similarly, high inspired oxygen concentrations may exacerbate
pulmonary dysfunction [11], through the generation of toxic free radicals or promotion of atelectasis
through nitrogen depletion. The conceptual shift cemented by the ARMA study was that poorly applied
mechanical ventilation increased mortality and that there was a balance between accepting less than ideal
arterial blood gases in order to avoid overly injurious mechanical ventilation [12].
The safe thresholds for arterial oxygen and carbon dioxide levels are not known. Arterial oxygen saturations
are the key parameter that relates to oxygen delivery and should be the primary focus rather than the arterial
oxygen tension. Indeed, the relationship between oxygen tension and saturation can be modified by many
factors in critical illness. Many patients tolerate some desaturation without demonstrating signs of
inadequate oxygen supply to the tissues, such as raised arterial lactate levels and impaired organ function.
However, hypoxaemia has been associated with neurocognitive dysfunction in patients who survive ARDS
[13]. Whilst the degree of hypoxaemia may be a surrogate for other processes, the concept of permissive
severe hypoxaemia has never been tested [14], and cannot be advocated. Similarly, there is no specific
arterial carbon dioxide tension (PaCO2) that is known to be ‘‘safe’’. Survival has been reported for PaCO2
levels as high as 30 kPa [15] and hypercapnia may limit pulmonary inflammation and injury [16]. In
contrast, respiratory acidosis can be associated with cardiovascular instability and pulmonary hypertension.
Typically a PaCO2 that results in a pH of o7.20 is cited as ‘‘safe’’, although this threshold is based on animal
data [17, 18] and has never been subject to formal investigation.
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FIGURE 3 Typical extracorporeal membrane oxygen circuit. Centrimag is manufactured by Thoractec (Pleasanton, CA,
USA) and HiLite is manufactured by Medos AG (Stolberg, Germany).
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What is the ideal tidal volume in a patient with ARDS? Some interpret the original ARMA study as
demonstrating that the 12.1 mL?kg-1 tidal volume given to the control group in the study was injurious [19]
but also not reflective of standard practice. The corollary and most conservative interpretation of the data is
that the ARMA study proved that these tidal volumes must be avoided. However, most clinicians aim for a
tidal volume of 6 mL?kg-1 predicted body weight, just fractionally less than the 6.2 mL?kg-1 delivered on days
1 and 3 in the lower tidal volume arm of the study. Calculation of predicted body weight from the patient’s
height is important but frequently not performed [20]. Analysis of 3000 consecutive admissions at the author’s
institution suggests that utilising actual body weight would result in 67% of patients being given a tidal volume
.10% of what was intended. Quick reference tables can assist clinicians at the bedside (table 1).
Tidal volumes of 6 mL?kg-1 are unlikely to be appropriate for all. Data from computed tomography (CT)
examinations of patients with ARDS suggest that hyperinflation can be present, even at tidal volumes of
6 mL?kg-1 [21]. The group of patients with hyperinflation tended to need higher plateau pressures to
achieve the 6 mL?kg-1 than those that had less hyperinflation (28.9¡0.9 versus 25.5¡0.5 cmH2O).
Subsequent studies demonstrated that hyperinflation was associated with more extensive consolidation on
CT scans and increased levels of inflammatory cytokines (interleukin (IL)-6, IL-8, 1L-1b and IL-1 receptor
antagonist) in bronchoalveolar lavage fluid. This cytokine signal was abolished within 72 h if the tidal
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FIGURE 4 Oxygen uptake and carbon dioxide removal in the membrane lung. a) The oxygen dissociation curve for
blood. b) The carbon dioxide dissociation curve for blood. The arrow represents the change in gas tension and gas
content of blood that typically occurs in the membrane lung. Haemoglobin: 110 g?L-1. PO2: oxygen tension; PCO2: carbon
dioxide tension.
TABLE 1 Quick reference table for calculating upper tidal volume limit in acute respiratory
distress syndrome
Height cm 6 mL?kg tidal volume-1#
Male Female
140–145 200
140–145 145–150 230
145–150 150–155 260
150–155 155–160 285
155–160 160–165 315
160–165 165–170 340
165–170 170–175 370
170–175 175–180 395
175–180 180–185 420
180–185 185–190 450
185–190 190–195 475
190–195 505
The table presents approximate height range targets for males and females. #: calculated from the predicted
body weight as determined in the ARMA study [8].
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volume was reduced further to achieve a plateau pressure of ,28 cmH2O. Arterial hypercapnia was
managed with ECCO2R if necessary [22]. The plateau pressure of ,26 cmH2O has appeared important in
other settings. In a re-analysis of the patient receiving 6 mL?kg-1 tidal volumes in the ARMA study, there
was a positive correlation between the required plateau pressure and mortality and an inflection point of
,26 cmH2O above which mortality increased more significantly [23]. In another study of patients receiving
ECMO for severe influenza A infection, survivors had a mean plateau pressure of 25¡3 cmH2O, in contrast
to nonsurvivors who had a mean plateau pressure of 29¡5 cmH2O [24].
It is not known whether high tidal volumes are acceptable in patients who spontaneously trigger the
mechanical ventilator with low ventilatory driving pressures. Spontaneous diaphragmatic activity may result
in more homogenous ventilation. Often significant respiratory effort and very negative intrapleural
pressures are masking poor lung compliance. A single animal study demonstrated significant pulmonary
damage in sheep that hyperventilated following an injection of sodium salicylate into their cisterna magna
[25]. This damage was not prevented by the administration of inspired carbon dioxide so as to maintain
normocarbia during hyperventilation. Paralysis and mechanical ventilation with normal tidal volumes were
not associated with pulmonary damage in the sheep. In general, many clinicians are equally concerned by
high tidal volumes, whether they are mandatory or spontaneously triggered, although there are few data to
support this assertion.
Taking these data together, my personal opinion as to what constitutes lung protective ventilation is a tidal
volume of f6 mL?kg-1 predicted body weight so as to maintain the plateau pressure below 26 cmH2O. In
the setting of lung resections, it is probably appropriate to reduce the tidal volume target further in
proportion with the amount of lung resected. In the scenario of impaired chest wall mechanics, such as a
marked kyphoscoliosis or extreme obesity, transpulmonary pressures will be less than anticipated and more
liberal plateau pressures may be acceptable. These targets can be difficult to achieve with acceptable blood
gases, particularly if significant amounts of positive end-expiratory pressure (PEEP) are used. The definition
has never been subjected to a formal evaluation.
Venoarterial ECMO
Venoarterial ECMO is less frequently employed in ARDS unless there is significant associated cardiac
dysfunction. Significant right ventricular dysfunction can occur in severe ARDS due to acute increases in
the pulmonary vascular resistance. This can result in a low cardiac output state, although this often
improves during venovenous ECMO as pulmonary vascular resistance falls due to oxygenation of
pulmonary arterial blood, better carbon dioxide control and a reduction in mechanical ventilatory driving
pressures. Severe sepsis can also cause significant myocardial dysfunction [26].
Peripheral venoarterial ECMO (fig. 2a) in the setting of severe pulmonary dysfunction and some residual
cardiac function can result in an interesting phenomenon, often referred to as Harlequin syndrome [27].
Peripheral venous cannulae often do not drain the complete cardiac output through the circuit. This results
in a residual native cardiac output through the heart and lungs. In the setting of severe respiratory failure
blood will remain desaturated in the pulmonary vein and will ultimately be ejected from the left ventricle.
This desaturated blood will meet well oxygenated blood from the ECMO circuit travelling up the aorta in a
retrograde manner. The balance between the two circulations influences where the transition between
deoxygenated and oxygenated blood occurs in the aortic arch. It is possible that the first vessels that leave
the aorta (coronary arteries and vessels to the upper body) received deoxygenated blood from the left
ventricle whilst the abdominal organs and lower body are supplied with oxygenated blood from the ECMO
circuit. An elegant solution is to undertake a hybrid venovenous arterial ECMO approach (fig. 2b) where
there is additional pre-pulmonary oxygenation.
The risks of ECMO
Bleeding complications are predominant in venoarterial ECMO and venovenous ECMO. Data from the
international registry suggest that the incidence of gastrointestinal haemorrhage is ,4%, surgical site
bleeding is ,13% and cannulation site bleeding is ,17% [28]. The most feared complication is intracranial
haemorrhage, which is reported in 4–8% of cases [28–30]. It is not only associated with significant mortality
but also significant functional impairment.
The risk of bleeding is not in keeping with the amount of heparin administered to prevent clotting within
the extracorporeal circuit. ECMO is associated with other disorders of clotting, such as platelet dysfunction
[31], acquired von Willebrand factor deficiency [32] and consumption of coagulation factors [33–35].
Bleeding can be massive and is best managed with the assistance of both surgical and haematological
colleagues. It often requires multiple surgical procedures, large numbers of blood products [36] and
temporary cessation of heparin therapy.
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Evidence
ECMO
ECMO has been tested in several studies. ZAPOL et al. [2] randomised 90 patients to receive venoarterial
ECMO or ventilation alone. Mortality was 90.5% and 91.7% in the ECMO and control groups, respectively.
Patients receiving ECMO support needed 1000–2500 mL of blood products each day. Patients died of
relentlessly progressive respiratory failure, probably due to that fact that mechanical ventilation was not
adjusted to what we now consider as protective settings. GATTINONI et al. [37] and MORRIS et al. [3]
investigated the effects of low flow ECMO, essentially carbon dioxide removal, to allow ‘‘lung rest’’, which
was proposed as a reduction in respiratory rate to ,3–4 breaths per minute. Peak airway pressures were
.35 cmH2O. Whilst survival was improved in contrast to the previous study and historical controls,
ECMO did not reduce mortality in comparison with conventional ventilation as practiced at that time.
Blood loss remained .1000 mL per day. These well undertaken studies need to be interpreted in the context
of mechanical ventilation, which we would nowadays consider as injurious to the lung and patient.
Nevertheless, some centres demonstrated much better outcomes in venovenous ECMO [38]. This formed
the basis for another randomised trial which was undertaken in the UK in 2009, the CESAR (Conventional
ventilation or ECMO for Severe Adult Respiratory failure) study. In a heterogeneous group of patients with
ARDS, this study demonstrated that transfer to an ECMO centre was associated with a 16% higher
incidence of survival without severe disability. ECMO was provided along with a number of interventions,
including fluid management and pressure-limited ventilation (peak airway pressure of 20–25 cmH2O, PEEP
10–15 cmH2O, respiratory rate of 10 breaths per min and fraction of inspired oxygen of 0.3). The
limitations of the study have been widely discussed and include its single centre design, crossovers in that
not all patients randomised to ECMO received ECMO, and lack of protocolised care in the conventionally
managed arm. This resulted in differences between the groups that could have confounded the results. The
higher use of corticosteroids and artificial liver support in patients cared for at the ECMO centre are
unlikely to have impacted on survival, as neither have been demonstrated to influence mortality [39, 40]. In
contrast, the greater use of low pressure and low volume ventilation in the patients at the ECMO centre
could be a very significant confounder, representing better processes at the ECMO centre. Alternatively, and
probably more likely, ECMO facilitated the persistent adoption of low tidal volumes and pressures and this
was the mechanism of benefit in the study.
In the winters of 2009/2010 and 2010/2011, ECMO was used with success in the management of some
patients with severe respiratory failure associated with pandemic influenza A (H1N1/09) infection. Case
series demonstrated survival rates ranging from 64% to 72.5% in cohorts of patients who the attending
clinicians felt were failing conventional therapies and had life-threatening hypoxaemia [24, 29, 30, 41]. The
cases series all coupled ECMO support with robust lung protective ventilation. Two groups undertook case-
matched analyses to compare outcomes in the cohort of ECMO patients to similar patients identified in
their national registries of patients admitted to intensive care units with H1N1/09 influenza A-related
respiratory failure [24, 29]. Matching was based on a priori defined variables that were considered to
possibly impact upon outcome. The study from the UK demonstrated that mortality was approximately
halved in patients who were referred and admitted to an ECMO centre [29]. In contrast, the French study
demonstrated no difference in outcome [24]. The analyses differed in terms of the variables inputted into
the models, statistical techniques and the size of the pool of potential case matches. Re-analysis of both
datasets using the statistical techniques of the alternative manuscript continues to produce conflicting
results. Interestingly, the service delivery model differs between the two countries with the 80 cases being
centralised to five ECMO centres in the UK and 127 patients being cared for in 35 ECMO centres in France.
How this impacts upon outcome is not known. Nevertheless, the excellent outcomes in patients with H1N1/
09 influenza following the CESAR study have significantly contributed to the enthusiasm for ECMO in
respiratory failure with refractory hypoxaemia. Overall, it appears that lung protective ventilation is an
essential and non-negotiable part of the ECMO package. Indeed ECMO is only a method of support and
does not directly impact on the underlying pulmonary process, aside from creating a scenario where
mechanical ventilation may be less damaging. Indeed, it is not necessary to mechanically ventilate patients
with ARDS who are on ECMO [42]. There is great interest in ‘‘awake ECMO’’ for patients with ARDS as it
is proposed that this may avoid some of the deleterious effects of mechanical ventilation, sedation and
immobilisation in the bed.
When ECMO should be employed remains controversial. Some would only employ it as rescue in
catastrophic hypoxaemia. The CESAR study used, in part, the lung injury score or Murray score in an
attempt to define severe respiratory failure that was failing conventional therapies but was not quite
catastrophic or futile. The lung injury score is a composite score that ranges between 0 and 4 [43]. It
evaluates PEEP, dynamic compliance, oxygenation and chest radiography. Higher values are meant to
reflect worse lung injury. Patients were typically recruited at,36 h after tracheal intubation and mechanical
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ventilation. The ELOIA (Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress
Syndrome) study, an international multicentre randomised controlled trial, is investigating whether early
implementation of ECMO within 6 h is beneficial (ClinicalTrials.gov identifier number NCT01470703).
Current practice in the UK is to use the criteria employed in the CESAR study. Patients are considered for
ECMO if they have a lung injury score .3 despite optimal management with lung protective ventilation.
Optimal management probably also includes prone ventilation [44] and neuromuscular blockade. In some
patients, the clinical decline is so rapid that there is insufficient time to optimise conventional therapy.
Patients must have potentially reversible respiratory failure and have no contraindication to anticoagulation
or ongoing life support. More than 7 days of injurious mechanical ventilation prior to ECMO is considered
a relative contraindication as outcomes are significantly poorer in patients ventilated for a prolonged time
prior to ECMO [45–49]. It is hypothesised that this is due to the irreversible establishment of significant
ventilator-associated lung injury by prolonged injurious ventilation.
ECCO2R
To date, there is one study of ECCO2R in 79 patients with moderate-to-severe ARDS and a plateau pressure
.25 cmH2O [50]. The investigators hypothesised that a tidal volume ,6 mL?kg
-1 would improve outcomes
by further limiting ventilator-associated lung injury. Patients were randomised to receive tidal volumes of
6 mL?kg-1 or 3 mL?kg-1, the latter facilitated by the concomitant use of ECCO2R. Patients with severe
hypoxaemia received ECMO. The ECCO2R system used was the arteriovenous pumpless iLA (Novalung
GmbH). There were no differences in the primary outcomes of ventilator-free days at day 28 and day 60. Post
hoc analysis suggested that patients who were more hypoxaemic and survived tended to wean faster and that it
may be worth investigating the role of ECCO2R in this more severe group of patients. The SUPERNOVA (A
Strategy of Ultra Protective Lung Ventilation with Extracorporeal CO2 Removal for New-Onset Moderate to
Severe ARDS) study, backed by the European Society of Intensive Care Medicine, is currently being set up and
may help answer this question. The patients in whom lung protective ventilation is difficult to achieve tend to
have more extensive pulmonary consolidation and severe hypoxaemia. Thus, the size of the cohort of patients
that may benefit from ECCO2R (whilst not requiring ECMO), and the lower blood flow in the extracorporeal
circuit is not clear. The risk–benefit balance is also influenced by the relative effects of pulmonary oxygen
toxicity, concomitant use of prone ventilation and acceptable oxygen saturations.
Long-term outcomes in survivors of ECMO
Rehabilitation following a period of respiratory ECMO can take a long time. Indeed, survivors of ARDS
who do not require ECMO demonstrate changes over time when followed up for 5 years [51, 52]. Thus,
assessments of health and quality of life will differ according to the time point at which they were measured.
Nevertheless, ECMO survivors have comparable outcomes to those who did not need ECMO when this is
assessed using the 36-item Short-Form Health Survey (SF-36) or EuroQoL questionnaire [53–55], although
this is less than for an age- and sex-matched population. Return to work is often limited or delayed [53] and
there are significant psychological sequelae [56]. Nevertheless, respiratory ECMO patients score higher on
the individual domains of the SF-36 than patients on chronic renal dialysis or patients who suffer with New
York Heart Association class III heart failure [57, 58].
Models of care
ECMO support requires assistance from many specialities within an organisation, including clinical
perfusion, haematology and surgery. Bedside nurses and critical care physicians need specific knowledge
and competencies to safely maintain the circuit. Often patients are absolutely dependent on the circuit and
may not be able to survive a failure triggered by inadvertent air entrainment or thrombosis. There are
modifications to many of the other intensive care unit processes too. For example, the routine and
seemingly innocuous insertion of a nasogastric feeding tube can be associated with massive haemorrhage.
This brings a burden of training to an ECMO centre that is not insignificant. ELSO have endeavoured to
define the knowledge and competencies that ECMO specialists require [59].
Other care is essential for a patient with severe respiratory failure. The vital nature of appropriate
mechanical ventilation has been described previously. Ensuring the correct diagnosis is made, avoiding
ventilator-associated pneumonia, managing pneumothoraces and air leaks, careful fluid management and
rehabilitation are also important. This requires radiologists, sub-speciality respiratory physicians,
cardiologists, thoracic surgeons, infectious disease specialists, and therapists and physicians expert in
rehabilitation following an episode of severe critical illness.
The training burden and infrastructure requirements favour the regionalisation of care to ECMO centres.
Regionalisation of care mandates that referral centres can provide mobile ECMO services so patients
admitted to other institutions can receive definitive support as soon as possible. There are some data that
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suggest that increased numbers of cases may be associated with better outcomes for mechanical ventilation
per se [60] and ECMO [61, 62]. This relationship is far from proven and other factors, such as organisation
culture and an ability to learn, have a huge impact. Undoubtedly low volume centres have to consider and
make special governance arrangements to sustain their knowledge and competencies. The development of
risk-adjustment models may facilitate benchmarking between centres [45, 47].
Conclusion
Venovenous ECMO support can avert life threatening hypoxaemia and hypercapnia, and can crucially
facilitate lung protective ventilation in patients with severe ARDS. The CESAR study demonstrated
improved survival without severe disability in patients transferred to an ECMO centre. Patients with
influenza A (H1N1/09) had good outcomes on ECMO. These results may corroborate the results from
CESAR but might not be generalisable outside the population of patients with severe influenza respiratory
disease. Nevertheless, ECMO centres continue to report high survival rates for patients who are supported
with ECMO. The patients return to a reasonable quality of life, albeit over a rehabilitation period that is
often very prolonged. The main controversy regarding ECMO is when should it be employed? As a rescue
therapy in profound hyopoxaemia and hypercarbia or earlier in the natural history of the process
to enhance lung protective ventilation? The ELOIA and SUPERNOVA studies will endeavour to answer
these questions.
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